Immunic, Inc. (NASDAQ:IMUX) Receives $12.25 Consensus Target Price from Brokerages

Shares of Immunic, Inc. (NASDAQ:IMUX) have been given a consensus recommendation of “Buy” by the seven analysts that are currently covering the firm, Marketbeat reports. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $11.80.

IMUX has been the subject of a number of analyst reports. B. Riley began coverage on Immunic in a research report on Tuesday, August 27th. They issued a “buy” rating and a $6.00 price target for the company. EF Hutton Acquisition Co. I raised Immunic to a “strong-buy” rating in a report on Monday, September 16th. Leerink Partnrs upgraded Immunic to a “strong-buy” rating in a research report on Monday, September 9th. StockNews.com downgraded shares of Immunic from a “hold” rating to a “sell” rating in a report on Monday, November 11th. Finally, Leerink Partners reiterated an “outperform” rating and issued a $5.00 price target on shares of Immunic in a report on Monday, September 9th.

Immunic Price Performance

IMUX stock opened at $1.18 on Friday. The stock’s fifty day moving average price is $1.39 and its 200-day moving average price is $1.34. The company has a market cap of $106.29 million, a P/E ratio of -0.96 and a beta of 1.88. Immunic has a 1 year low of $0.97 and a 1 year high of $2.11.

Insider Buying and Selling

In related news, Director Richard Alan Rudick purchased 87,300 shares of Immunic stock in a transaction that occurred on Tuesday, November 12th. The shares were bought at an average price of $1.15 per share, with a total value of $100,395.00. Following the purchase, the director now directly owns 87,300 shares of the company’s stock, valued at approximately $100,395. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 3.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Immunic

Institutional investors and hedge funds have recently modified their holdings of the stock. BVF Inc. IL bought a new position in Immunic during the 1st quarter worth about $11,752,000. Janus Henderson Group PLC purchased a new stake in shares of Immunic during the first quarter valued at about $9,266,000. Vanguard Group Inc. increased its position in Immunic by 100.7% during the 1st quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock valued at $4,480,000 after buying an additional 1,703,047 shares in the last quarter. Ikarian Capital LLC boosted its holdings in Immunic by 258.3% in the first quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock worth $2,128,000 after acquiring an additional 1,162,378 shares in the last quarter. Finally, State Street Corp increased its holdings in shares of Immunic by 7.5% during the third quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after acquiring an additional 11,642 shares in the last quarter. Institutional investors own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.